Corporate Culture - About us - AG8旗舰厅生物


  • AG8旗舰厅

    About Sciarray

    Professional and more focused

    About us

       

    Sciarray specializes in developing proprietary biological technologies which have led to the development of a pipeline of clinical diagnostic products in five immunological and molecular methods: ELISA, chemiluminescent immunoassay(CLIA) ,biological chip , rapid biochemical test , gene methylation and medical devices.

    As a leading provider of China' s clinical diagnostical and research products in past few years, Sciarray begins to be a main, broad-based health care company devoted to discovering new clinical and laboratory methods, new technologies and new ways to manage the disease diagnosis.   

    Sciarray has been driven by a constant goal: to advance medical laboratory science to help clinical technicans to work more efficient , convenient and time-saving, to make people free from tough laboratory work. That' s our commitment. The promise of our company is in the promise that our work holds for health and for easy life.


    Corporate Culture

    Corporate Mission

    Corporate Mission

    Innovative Life Technology For Serving Human Health

    Corporate vision

    Corporate vision

    Innovation Pioneer of IVD Industry

    Core values

    Core values

    Continuous innovation and pursuiting for excellence

    Development philosophy

    Development philosophy

    Respection, achievement, trust, innovation, openness, professionalism

    2022 Development
    DEVELOP

    2022

    State Food and Drug Administration's innovative medical device products: systemic lupus erythematosus gene methylation detection reagent "Termine" is about to be launched! It will fill the gap of genetic diagnosis of systemic lupus erythematosus at home and abroad, and improve the diagnosis and treatment standards.

    2021 Development
    DEVELOP

    2021

    Microarray antinuclear antibody spectroscopy products (the only ones at home and abroad) and urinary iodine detection reagents have won the registration certificate and are officially on the market.

    2020 Development
    DEVELOP

    2020

    The Systemic Lupus Erythematosus Gene Methylation Marker Detection Kit was awarded the NMPA Special Approval for Innovative Medical Devices.

    2018 Development
    DEVELOP

    2018

    Antinuclear antibody profile, urinary iodine detection, allergen detection chip declaration and registration.

    2017 Development
    DEVELOP

    2017

    The microarray reader obtained the registration certificate and went on sale. Breakthroughs have been made in multiplex antibody detection products and methylation detection products for respiratory pathogens.

    2016 Development
    DEVELOP

    2016

    The automatic microarray reactor was successfully developed, and the diabetes chip and infertility chip were registered and sold, and won the 2016 Shenzhen Science and Technology Progress Award.

    2015 Development
    DEVELOP

    2015

    "Research and industrial application of key technologies of protein chips" won the second prize of Shenzhen Science and Technology Progress Award

    2022

    2021

    2020

    2018

    2017

    2016

    2015

    Tel

    Tel
    +86 (0)755-26623699
    26625938

    WeChat

    AG8旗舰厅